Premium
Momordica Charantia (Bitter Melon) Inhibits Primary Human Adipocyte Differentiation by Modulating Adipogenic genes
Author(s) -
Nerurkar Pratibha Vivek,
Lee Yun Kyung,
Nerurkar Vivek R.
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.335.6
Subject(s) - perilipin , adipogenesis , lipolysis , adipocyte , momordica , endocrinology , medicine , lipogenesis , lipid droplet , adipose tissue , peroxisome , peroxisome proliferator activated receptor , adipose triglyceride lipase , biology , receptor , traditional medicine
Momordica charantia or bitter melon (BM) that is traditionally used to treat diabetes and complications has been demonstrated to alleviate hyperglycemia as well as reduce adiposity in rodents. The objective of our study was to investigate the effects of BM juice (BMJ) on lipid accumulation and adipocyte differentiation factors in primary human preadipocytes and differentiated adipocytes. Preadipocytes treated with varying concentrations of BMJ during differentiation significantly reduced lipid accumulation as well as the mRNA expression of peroxisome proliferator‐associated receptor (PPAR), sterol regulatory element‐binding protein 1c (SREBP‐1c) and resistin genes. Similarly, differentiated adipocytes treated with BMJ for 48 h demonstrated reduced lipid accumulation, perilipin mRNA expression, and increased lipolysis. Our data suggests that BM is a potent inhibitor of lipogenesis and stimulator of lipolysis activity in primary human adipocytes. BMJ may therefore prove to be an effective complementary or alternative therapy to induce anti‐obesity effects in humans. [Grants: NCCAM (R21AT003719), RCMI, NCRR (G12RRAI03061), NIH, and Hawaii Community Foundation (20041652)].